Study #2023-0031
Phase 2 trial of Epcoritamab in combination with Rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell Lymphoma.
MD Anderson Study Status
Enrolling
Treatment Agent
Prednisone, Rituximab, Cyclophosphamide, Vincristine, Epcoritamab
Description
To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Large B-cell Lymphoma
Study phase:
Phase II
Physician name:
Dai Chihara
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-855-645-0878
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.